Is generative pre-trained transformer artificial intelligence (Chat-GPT) a reliable tool for guidelines synthesis? A preliminary evaluation for biologic CRSwNP therapy.
Artificial intelligence
Biologic CRSwNP therapy
Generative pre-trained transformer (GPT)
Guidelines synthesis
Preliminary evaluation
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
15
11
2023
accepted:
08
01
2024
medline:
18
3
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
ppublish
Résumé
Biologic therapies for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) have emerged as an auspicious treatment alternative. However, the ideal patient population, dosage, and treatment duration are yet to be well-defined. Moreover, biologic therapy has disadvantages, such as high costs and limited access. The proposal of a novel Artificial Intelligence (AI) algorithm offers an intriguing solution for optimizing decision-making protocols. The AI algorithm was initially programmed to conduct a systematic literature review searching for the current primary guidelines on biologics' clinical efficacy and safety in treating CRSwNP. The review included a total of 12 studies: 6 systematic reviews, 4 expert consensus guidelines, and 2 surveys. Simultaneously, two independent human researchers conducted a literature search to compare the results. Subsequently, the AI was tasked to critically analyze the identified papers, highlighting strengths and weaknesses, thereby creating a decision-making algorithm and pyramid flow chart. The studies evaluated various biologics, including monoclonal antibodies targeting Interleukin-5 (IL-5), IL-4, IL-13, and Immunoglobulin E (IgE), assessing their effectiveness in different patient populations, such as those with comorbid asthma or refractory CRSwNP. Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, demonstrated significant improvement in nasal symptoms and quality of life in patients with CRSwNP in several randomized controlled trials and systematic reviews. Similarly, mepolizumab and reslizumab, which target IL-5, have also shown efficacy in reducing nasal polyp burden and improving symptoms in patients with CRSwNP, particularly those with comorbid asthma. However, additional studies are required to confirm the long-term efficacy and safety of these biologics in treating CRSwNP. Biologic therapies have surfaced as a promising treatment option for patients with severe or refractory CRSwNP; however, the optimal patient population, dosage, and treatment duration are yet to be defined. The application of AI in decision-making protocols and the creation of therapeutic algorithms for biologic drug selection, could offer fascinating future prospects in the management of CRSwNP.
Identifiants
pubmed: 38329526
doi: 10.1007/s00405-024-08464-9
pii: 10.1007/s00405-024-08464-9
doi:
Substances chimiques
Interleukin-5
0
Biological Products
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2167-2173Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Banoub RG, Hoehle LP, Phillips KM et al (2018) Depressed Mood Modulates Impact of Chronic Rhinosinusitis Symptoms on Quality of Life. J Allergy Clin Immunol Pract 6(6):2098–2105. https://doi.org/10.1016/j.jaip.2018.04.034
doi: 10.1016/j.jaip.2018.04.034
pubmed: 29751155
De Corso E, Pipolo C, Cantone E et al (2022) Survey on use of local and systemic corticosteroids in the management of chronic rhinosinusitis with nasal polyps: identification of unmet clinical needs. J Pers Med 12(6):897. https://doi.org/10.3390/jpm120608972
doi: 10.3390/jpm120608972
pubmed: 35743682
pmcid: 9225345
Rank MA, Chu DK, Bognanni A, Oykhman P, Bernstein JA, Ellis AK, Golden DBK, Greenhawt M, Horner CC, Ledford DK, Lieberman J, Luong AU, Orlandi RR, Samant SA, Shaker MS, Soler ZM, Stevens WW, Stukus DR, Wang J, Peters AT (2023) The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 151(2):386–398. https://doi.org/10.1016/j.jaci.2022.10.026
doi: 10.1016/j.jaci.2022.10.026
pubmed: 36370881
Haxel BR, Hummel T, Fruth K et al (2022) Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology 60(6):435–443. https://doi.org/10.4193/Rhin22.129
doi: 10.4193/Rhin22.129
pubmed: 36150163
La Mantia I, Grigaliute E, Ragusa M, Cocuzza S, Radulesco T, Saibene AM, Calvo-Henriquez C, Fakhry N, Michel J, Maniaci A (2023) Effectiveness and rapidity on olfatory fuction recovery in CRS patients treated with Dupilumab: a real life prospective controlled study. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-023-08184-6
doi: 10.1007/s00405-023-08184-6
pubmed: 37594543
pmcid: 10562315
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71. https://doi.org/10.1136/bmj.n71
doi: 10.1136/bmj.n71
Yang SK, Cho SH, Kim DW (2022) Interpretation of clinical efficacy of biologics in chronic rhinosinusitis with nasal polyps via understanding the local and systemic pathomechanisms. Allergy Asthma Immunol Res 14(5):465–478. https://doi.org/10.4168/aair.2022.14.5.465
doi: 10.4168/aair.2022.14.5.465
pubmed: 36174990
pmcid: 9523422
Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O (2020) Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 145(3):725–739. https://doi.org/10.1016/j.jaci.2020.01.020
doi: 10.1016/j.jaci.2020.01.020
pubmed: 32145872
Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, Mullol J, Gevaert P, Klimek L, Prokopakis E, Knill A, Cavaliere C, Hopkins C, Hellings P (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol 147(1):29–36. https://doi.org/10.1016/j.jaci.2020.11.013
doi: 10.1016/j.jaci.2020.11.013
pubmed: 33227318
Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee J, Lee SE, Mariën G, Pugin B, Senior B, Seys SF, Hellings PW (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312–2319. https://doi.org/10.1111/all.13875
doi: 10.1111/all.13875
pubmed: 31090937
Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, Scadding GK, Wagemann M, Bernal-Sprekelsen M, Chaker A, Heffler E, Han JK, Van Staeyen E, Hopkins C, Mullol J, Peters A, Reitsma S, Senior BA, Hellings PW (2023) EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. https://doi.org/10.4193/Rhin22.489
doi: 10.4193/Rhin22.489
pubmed: 37999634
Maza-Solano J, Biadsee A, Sowerby LJ, Calvo-Hernández C, Tucciarone M, Rocha T, Maniaci A, Saibene AM, Chiesa-Estomba CM, Radulesco T, Metwaly O, Lechien JR, Alobid I, Locatello LG (2023) Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey. Eur Arch Otorhinolaryngol 280(5):2309–2316. https://doi.org/10.1007/s00405-022-07762-4
doi: 10.1007/s00405-022-07762-4
pubmed: 36454385
Rampi A, Vinciguerra A, Tanzini U, Bussi M, Trimarchi M (2023) Comparison of guidelines for prescription and follow-up of biologics for chronic rhinosinusitis with nasal polyps. Eur Arch Otorhinolaryngol 280(1):39–46. https://doi.org/10.1007/s00405-022-07634-x
doi: 10.1007/s00405-022-07634-x
pubmed: 36098864
Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Solà I, Santero M, Akdis CA, Akdis M, Canonica GW, Chivato T, Del Giacco S, Eiwegger T, Fokkens W, Georgalas C, Gevaert P, Hopkins C, Klimek L, Lund V, Naclerio R, O’Mahony L, Palkonen S, Pfaar O, Schwarze J, Soyka MB, Wang Y, Zhang L, Canelo-Aybar C, Palomares O, Jutel M (2021) Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy 76(8):2337–2353. https://doi.org/10.1111/all.14809
doi: 10.1111/all.14809
pubmed: 33683704
Hopkins C, McKenzie JL, Anari S, Carrie S, Ramakrishnan Y, Kara N, Philpott C, Hobson J, Qureishi A, Stew B, Bhalla R, Gane S, Walker A, Harries P, Hathorn I, Lund V (2021) British Rhinological Society Consensus Guidance on the use of biological therapies for chronic rhinosinusitis with nasal polyps. Clin Otolaryngol 46(5):1037–1043. https://doi.org/10.1111/coa.13779
doi: 10.1111/coa.13779
pubmed: 33817954
Al-Ahmad M, Alsaleh S, Al-Reefy H, Al Abduwani J, Nasr I, Al Abri R, Alamadi AMH, Fraihat AA, Alterki A, Abuzakouk M, Marglani O, Rand HA (2022) Expert Opinion on Biological Treatment of Chronic Rhinosinusitis with Nasal Polyps in the Gulf Region. J Asthma Allergy 4(15):1–12. https://doi.org/10.2147/JAA.S321017
doi: 10.2147/JAA.S321017
Scadding GK, Scadding GW (2022) Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP) J Allergy Clin Immunol;49(3):895–897. doi: https://doi.org/10.1016/j.jaci.2021.10.029 .
Tversky J, Lane AP, Azar A (2021) Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. Clin Exp Allergy 51(6):836–844. https://doi.org/10.1111/cea.13852
doi: 10.1111/cea.13852
pubmed: 33595845
Bachert C, Han JK, Desrosiers MY et al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol 149(4):1309-1317.e12. https://doi.org/10.1016/j.jaci.2021.08.030
doi: 10.1016/j.jaci.2021.08.030
pubmed: 34599979
Takabayashi T, Asaka D, Okamoto Y et al (2021) A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. Am J Rhinol Allergy 35(6):861–870. https://doi.org/10.1177/19458924211009429
doi: 10.1177/19458924211009429
pubmed: 33840229
Canonica GW, Harrison TW, Chanez P et al (2022) Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy 77(1):150–161. https://doi.org/10.1111/all.14902
doi: 10.1111/all.14902
pubmed: 33978983
Weinstein SF, Katial RK, Bardin P et al (2019) Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract 7(2):589-596.e3. https://doi.org/10.1016/j.jaip.2018.08.021
doi: 10.1016/j.jaip.2018.08.021
pubmed: 30193936
Wong G, Greenhalgh T, Westhorp G, Pawson R (2014) Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the RAMESES (Realist And Meta-narrative Evidence Syntheses – Evolving Standards) project. Southampton (UK): NIHR Journals Library
Lechien JR, Maniaci A, Gengler I, Hans S, Chiesa-Estomba CM, Vaira LA (2023) Validity and reliability of an instrument evaluating the performance of intelligent chatbot: the Artificial Intelligence Performance Instrument (AIPI). Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-023-08219-y
doi: 10.1007/s00405-023-08219-y
pubmed: 38055045
pmcid: 10029791